Notably, 5-fluorouracil (5-FU), a key chemotherapeutic for CRC, also shows strong antimicrobial activity against Fusobacterium nucleatum (Fn), a bacterium linked to poor prognosis and chemoresistance (LaCourse et al., 2022). Here, FN1 is linked to colorectal carcinoma.